Accretion Pharmaceuticals (NSE:ACCPL) Notes Receivable: ₹0.0 Mil (As of Mar. 2026)


NSE:ACCPL Accretion Pharmaceuticals Ltd NSE:ACCPL
30 GF Score
Price ₹155.65
! 6 Warning Signs
View Full Analysis

What is Accretion Pharmaceuticals Notes Receivable?

Accretion Pharmaceuticals NSE:ACCPL -3.92% 30 Notes Receivable is ₹0.0 Mil as of Mar. 2026. GuruFocus rates NSE:ACCPL with a GF Score™ of 30/100. The stock has 6 warning signs investors should review.

Accretion Pharmaceuticals's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0.0 Mil.

Accretion Pharmaceuticals Notes Receivable Related Terms

Accretion Pharmaceuticals Notes Receivable Historical Data

* Premium members only.

The historical data trend for Accretion Pharmaceuticals's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accretion Pharmaceuticals Notes Receivable Chart

Accretion Pharmaceuticals Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Notes Receivable
0.00 0.00 0.00 0.00 0.00

Accretion Pharmaceuticals Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Notes Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
NSE:ACCPL
30GF Score
Accretion Pharmaceuticals Ltd NSE:ACCPL
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accretion Pharmaceuticals Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0.0 Mil mean?
Accretion Pharmaceuticals (NSE:ACCPL) has a Notes Receivable of ₹0.0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Accretion Pharmaceuticals and its competitors.
Is Accretion Pharmaceuticals' Notes Receivable too high?
Accretion Pharmaceuticals' current Notes Receivable is ₹0.0 Mil. Overall, Accretion Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' Notes Receivable compare to LLY and JNJ?
Accretion Pharmaceuticals' Notes Receivable of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Accretion Pharmaceuticals and its competitors. Accretion Pharmaceuticals's current Notes Receivable is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current Notes Receivable of ₹0.0 Mil. The current Notes Receivable is ₹0.0 Mil. Accretion Pharmaceuticals' overall GF Score™ is 30/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current Notes Receivable is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accretion Pharmaceuticals Business Description

Address 29, Xcelon Industrial Park-1, Behind Intas Pharmaceuticals, Vasna-Chacharwadi, Ta - Sanand District, Ahmedabad, GJ, IND, 382213
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
30GF Score

Get the complete analysis for NSE:ACCPL

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹155.65
Price